Molecular Composition, Signal Transduction Mechanisms, and Tissue Injury Regulation of the TWEAK-Fn14 Pathway
Molecular Composition, Signal Transduction Mechanisms, and Tissue Injury Regulation of the TWEAK-Fn14 Pathway
The TWEAK-Fn14 pathway is a signaling axis within the TNF superfamily that integrates inflammatory regulation, tissue remodeling, and cell fate control. Its biological significance does not lie in the single question of whether TWEAK induces apoptosis, but rather in how Fn14 receptor activation determines whether cells ultimately enter inflammatory, proliferative, migratory, reparative, or death-associated states through the TRAF-cIAP complex, the canonical and non-canonical NF-κB branches, MAPK/AKT modules, and cooperative cell death mechanisms.
Keywords: TWEAK; Fn14; TNFRSF12A; NF-κB; TRAF2; cIAP1; tissue remodeling; cell death
1 Basic Framework of the TWEAK-Fn14 Pathway
1.1 Ligand and Receptor Composition
(1) Molecular properties of TWEAK
TWEAK, or TNF-like weak inducer of apoptosis, is a ligand of the TNF superfamily. It was originally named because under specific conditions it exerts a relatively weak pro-apoptotic effect in certain cell types. Subsequent studies, however, have shown that the core function of TWEAK is not limited to apoptosis, but rather extends broadly to the regulation of inflammation, proliferation, and tissue responses.
(2) Receptor properties of Fn14
Fn14, or fibroblast growth factor-inducible 14, is encoded by the TNFRSF12A gene and is currently the only known functional receptor for TWEAK. Fn14 is one of the structurally smaller members of the TNF receptor superfamily, yet its signaling output is not weak. Instead, because of its inducible expression pattern, it can exert marked amplification effects in injured tissues.
(3) Receptor expression characteristics
Fn14 is usually expressed at low levels in homeostatic tissues, but can be markedly induced under conditions of injury, inflammation, regeneration, and pathological remodeling. Accordingly, the TWEAK pathway is more accurately viewed as an injury-responsive amplification axis rather than a constitutively high-activity homeostatic pathway.
1.2 Ligand Processing and Presentation Forms
(1) Membrane-bound and soluble TWEAK
TWEAK is synthesized as a precursor transmembrane protein and can subsequently be cleaved proteolytically to release soluble TWEAK. Both membrane-bound and soluble TWEAK are biologically active, but they are not equivalent in receptor clustering capacity or downstream signaling strength.
(2) Signaling differences between ligand forms
Membrane-bound TWEAK more readily triggers efficient Fn14 clustering and induces stronger canonical NF-κB activation. Soluble TWEAK can also activate Fn14-associated signaling, but its ability to drive the canonical NF-κB branch is generally weaker, while it can still effectively participate in non-canonical NF-κB activation and sensitize cells to other death pathways.
2 Early Signal Transduction of the TWEAK-Fn14 Pathway
2.1 Receptor-Proximal Complex
(1) TRAF recruitment
Although the cytoplasmic tail of Fn14 is short, it can recruit members of the TRAF family, particularly TRAF2-associated complexes. Following Fn14 activation, TRAF2 together with its associated cIAP1/cIAP2 proteins can be drawn into the receptor complex, thereby forming a key platform for subsequent signal branching.
(2) Rearrangement of the cIAP1-TRAF2 axis
TWEAK/Fn14 signaling can induce translocation and degradation of the cIAP1-TRAF2 complex. This process directly alters how cells respond to different NF-κB branches as well as to other TNF family signals. In other words, TWEAK does not simply transmit its own signal; it also reshapes cellular sensitivity to stimulation by other inflammatory receptors.
2.2 Canonical NF-κB Branch
(1) Activation conditions
When Fn14 clustering is sufficient, especially in the presence of membrane-bound TWEAK or higher-order clustered stimulation, TWEAK can activate the canonical NF-κB pathway and promote initiation of the RelA/p50-associated transcriptional program. This branch is commonly associated with upregulation of inflammatory mediators, chemokines, adhesion molecules, and genes involved in tissue remodeling.
(2) Functional outcomes
Canonical NF-κB output is generally associated with pro-inflammatory, pro-migratory, pro-proliferative, or tissue response-enhancing effects. In systems such as tubular epithelial cells, TWEAK can simultaneously trigger NF-κB, MAPK, and Akt activation and drive proliferation-related programs.
2.3 Non-Canonical NF-κB Branch
(1) Basis of activation
Because TWEAK/Fn14 can cause depletion of the TRAF2-cIAP complex, thereby stabilizing NIK and promoting processing of p100 into p52, this pathway represents one of the most characteristic non-canonical NF-κB activation axes downstream of Fn14.
(2) Functional bias
In models such as skeletal muscle cells, low-level TWEAK preferentially activates non-canonical NF-κB and is associated with differentiation-related events such as myoblast fusion. This indicates that the TWEAK pathway is not inherently biased toward inflammation or injury; rather, its output depends on stimulus strength, duration, and cellular context.
Table 1. Major Signaling Hierarchies of the TWEAK-Fn14 Pathway
Signaling hierarchy | Key molecules | Primary functions |
Ligand level | TWEAK | Receptor binding and signal initiation |
Receptor level | Fn14/TNFRSF12A | Receptor clustering and proximal complex assembly |
Proximal transduction level | TRAF2, cIAP1, cIAP2 | Signal branching and regulation of NIK stability |
Canonical NF-κB level | IKK complex, RelA/p50 | Transcription related to inflammation, migration, and proliferation |
Non-canonical NF-κB level | NIK, p100/p52, RelB | Differentiation, tissue remodeling, and sustained responses |
Cooperative death level | TNFR1, RIPK3, Caspase modules | Sensitization and amplification of cell death |
3 Non-NF-κB Outputs of the TWEAK-Fn14 Pathway
3.1 MAPK and AKT Modules
(1) MAPK activation
In multiple cell types, TWEAK can activate MAPK branches such as ERK, JNK, or p38. The outcome is not fixed and may manifest as enhanced inflammation, increased migration, or transcriptional changes associated with injury repair.
(2) AKT-related outputs
Studies in models such as tubular cells have shown that TWEAK can also activate Akt signaling and participate in proliferative responses under non-inflammatory conditions. This indicates that TWEAK is linked not only to cellular injury but also, in specific microenvironments, to compensatory proliferation and repair-associated functions.
3.2 Cell Death-Related Outputs
(1) Limited direct apoptotic activity but strong context dependence
Although the name TWEAK includes “weak inducer of apoptosis,” its direct pro-apoptotic capacity is usually limited and often becomes evident only under specific sensitizing conditions. More commonly, its role is not to induce death independently, but to lower the threshold for cell death in an appropriate biological context.
(2) Death-sensitizing effect
A more common feature of TWEAK is to increase cellular sensitivity to other death-inducing stimuli. It can enhance TNFR1-mediated apoptotic or necrotic-like outputs and can also amplify death signaling under stress conditions, including promotion of necroptosis-like responses.
(3) Death effects in specific tissues
In neurons and cerebral ischemia models, the TWEAK-Fn14 axis can induce outputs associated with PARP-1 activation, caspase-3 cleavage, and cell death, suggesting that this pathway can directly participate in cell death programs in central nervous system injury.
4 Major Biological Functions of the TWEAK-Fn14 Pathway
4.1 Inflammation and Chemotaxis
(1) Inflammatory amplification
TWEAK-Fn14 can induce expression of multiple inflammation-related genes and therefore often acts as an inflammatory amplifier after tissue injury. Its role is generally not to determine whether inflammation occurs, but rather to increase the intensity of responses within an already injured environment.
(2) Synergy with other cytokines
The TWEAK pathway can act synergistically with TNF, IFN-γ, and pattern recognition receptor signaling. Accordingly, its pathological role often lies in co-amplification with other inflammatory axes rather than in isolated action.
4.2 Proliferation, Migration, and Tissue Remodeling
(1) Repair- and regeneration-related outputs
TWEAK is not always a harmful signal. In non-inflammatory or early repair settings, it can promote proliferation of certain epithelial cells or progenitor cells and participate in tissue regeneration and compensatory responses.
(2) Fibrosis and remodeling
If Fn14 remains highly expressed after injury, TWEAK signaling may shift from short-term repair toward chronic inflammation and pro-fibrotic activity. Thus, this pathway displays marked biphasic behavior: it may participate in repair in the short term, whereas persistent activation tends to drive pathological remodeling.
5 Disease Associations of the TWEAK-Fn14 Pathway
5.1 Renal Injury
(1) Acute kidney injury
In the kidney, Fn14 is markedly upregulated in models of ischemia-reperfusion and toxic injury. The TWEAK/Fn14 axis can contribute to tubular inflammation, cell death, and post-injury responses, and its upregulation is therefore often associated with the severity of acute injury.
(2) Biphasic effects on proliferation and injury
The same pathway can exhibit dual behavior in different renal microenvironments: it promotes tubular epithelial proliferation under non-inflammatory conditions, but amplifies inflammation and tissue damage in inflammatory acute injury settings.
5.2 Skeletal Muscle and Tissue Repair
(1) Muscle remodeling
The TWEAK-Fn14 axis participates in regulation of muscle biology. Under certain conditions, low-level TWEAK can promote myoblast fusion through non-canonical NF-κB, whereas persistent or aberrant signaling is associated with muscle atrophy, inflammation, and fibrotic tendencies.
5.3 Central Nervous System Injury
(1) Ischemia and neuronal death
Studies in the nervous system have shown that TWEAK-Fn14 interaction can promote neuronal death associated with cerebral ischemia and is linked to PARP-1 activation and caspase-3 cleavage, indicating a pathological amplification role in brain injury.
5.4 Tumors
(1) Inducible receptor expression
Elevated Fn14 expression has been widely observed in multiple tumor types. Its significance is not uniform: in some settings, TWEAK can enhance tumor cell death sensitivity, whereas in others it is more closely associated with tumor cell migration, invasion, or inflammation-like survival programs.
(2) Context dependence of pathological outputs
Accordingly, the TWEAK-Fn14 pathway cannot be simply classified as either pro-tumorigenic or anti-tumorigenic. Its actual function depends on Fn14 expression level, the cell death context, inflammatory status, and its coupling to other TNF family signals.
Table 2. Major Functional Outputs and Pathological Contexts of the TWEAK-Fn14 Pathway
Functional hierarchy | Major outputs | Representative contexts |
Inflammatory amplification | Upregulation of chemokines, adhesion molecules, and inflammatory transcriptional programs | Acute injury, chronic inflammation |
Proliferation/repair | Proliferation of epithelial or progenitor cells and tissue compensation | Tubular proliferation, regenerative responses |
Non-canonical remodeling | Differentiation, fusion, and sustained responses | Skeletal muscle remodeling |
Death sensitization | Enhanced apoptosis, necrotic-like death, or cooperative cell death | Tumor cells, infection models, or stress models |
Fibrosis progression | Chronic inflammation-associated remodeling and scar formation | Chronic organ injury |
6 Experimental Analysis and Interpretation of the TWEAK-Fn14 Pathway
6.1 Common Readouts
(1) Ligand and receptor expression
Expression of TWEAK and Fn14 represents the most basic pathway readout, but Fn14 is more decisive because inducible elevation of Fn14 is the prerequisite for pathway amplification in many systems.
(2) Proximal signaling indicators
Changes in TRAF2, cIAP1/cIAP2 status, and NIK stability can be used to determine whether proximal complex rearrangement has occurred.
(3) Canonical and non-canonical NF-κB readouts
Indicators such as IκB degradation, RelA nuclear translocation, p100-to-p52 processing, and RelB activation can distinguish the relative contribution of the two NF-κB branches.
(4) Functional-layer readouts
Cell proliferation, migration, inflammatory mediator release, caspase activation, PARP cleavage, and RIPK3-dependent death should be selected according to the specific model and cannot be summarized by a single indicator for all TWEAK outputs.
6.2 Common Biases in Data Interpretation
(1) Equating TWEAK with an apoptotic factor
TWEAK was originally named for its weak pro-apoptotic effect, but in most systems its more central feature is context-dependent regulation of inflammation and remodeling rather than stable, potent direct induction of apoptosis.
(2) Neglecting differences between ligand forms
Failure to distinguish membrane-bound TWEAK from soluble TWEAK may lead to misinterpretation of canonical NF-κB activation strength and downstream inflammatory output.
(3) Neglecting cellular context
TWEAK outputs differ substantially among tubular epithelial cells, neurons, myoblasts, and tumor cells. Results from one model therefore cannot be directly extrapolated to all tissues.
Table 3. Key Readouts for Experimental Analysis of the TWEAK-Fn14 Pathway
Observation level | Common indicators | Methodological significance |
Ligand/receptor level | TWEAK, Fn14 | Determines whether the pathway has the basis for activation |
Proximal complex level | TRAF2, cIAP1/2, NIK | Determines whether proximal signaling has been rearranged |
Canonical NF-κB level | IκB, RelA/p50 | Assesses the strength of inflammatory-type outputs |
Non-canonical NF-κB level | p100/p52, RelB | Assesses sustained remodeling- and differentiation-related outputs |
Functional level | Proliferation, migration, apoptosis, necrotic-like death | Determines the terminal biological outcome |
7 Product Tables Related to the TWEAK-Fn14 Pathway
Table 4. Core Axis Product Table for the TWEAK-Fn14 Pathway
Product type | Catalog No. | Name | Grade and Purity | Suitable research direction/use |
TWEAKR/Fn14-targeting antibody | Enavatuzumab (anti-TWEAKR) | Animal Free, Carrier Free, Recombinant, Validated, ExactAb™, Low Endotoxin, Azide Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA | Suitable for TWEAKR/Fn14 blockade, receptor functional intervention, and mechanistic validation | |
TWEAKR/Fn14 recombinant protein | Recombinant Human TWEAK R/TNFRSF12 Protein | Animal Free, Carrier Free, Bioactive, ActiBioPure™, Azide Free, High Performance, His Tag, Fc tag, ≥92%(SDS-PAGE) | Suitable for Fn14 receptor binding, ligand interaction, and in vitro functional studies | |
TWEAKR/Fn14 antibody | Recombinant TWEAKR/FN14 Antibody | Recombinant, Validated, ExactAb™, See COA | Suitable for TWEAKR/FN14 protein detection and expression analysis | |
TWEAK ligand | TWEAK | Moligand™ | Suitable for exogenous TWEAK stimulation, Fn14 activation, and pathway modeling | |
TWEAK detection kit | Human Soluble Tumor Necrosis Factor-like Weak Inducer Of Apoptosis (sTWEAK) ELISA Kit | BioReagent | Suitable for quantitative detection of human sTWEAK | |
TWEAK detection kit | Rat Tumor Necrosis Factor-related Weak Apoptosis-inducing Factor(TWEAK) ELISA Kit | BioReagent | Suitable for quantitative detection of rat TWEAK |
Table 5. Cell Death Validation Product Table Related to the TWEAK Pathway
Product type | Catalog No. | Name | Grade and Purity | Suitable research direction/use |
Caspase-8 inhibitor | Ac-IEPD-CHO | ≥95% | Suitable for validating caspase-8 dependence in TWEAK-related extrinsic death signaling | |
Caspase-8 chromogenic substrate | Ac-IETD-pNA, TFA salt | ≥98% | Suitable for detecting caspase-8 activation | |
Caspase-8 antibody | Caspase 8 Mouse mAb | KD Validation | Suitable for caspase-8 protein detection | |
Caspase-8 activity assay kit | Caspase 8 Activity Assay Kit | BioReagent | Suitable for detecting changes in caspase-8 activity | |
Caspase-8 activity assay kit | Caspase 8 Activity Assay Kit | BioReagent,Suitable for Analysis, Colorimetry | Suitable for colorimetric detection of caspase-8 activity | |
Cleaved Caspase-8 antibody | Cleaved Caspase 8 Antibody | KD Validation | Suitable for detection of cleaved caspase-8, an important readout of TWEAK death output | |
Recombinant Caspase-8 antibody | Recombinant Caspase-8 Antibody | Recombinant, ExactAb™, Validated, Lot by Lot | Suitable for caspase-8 protein detection | |
Recombinant Caspase-8 protein | Recombinant Human Caspase-8 Protein | Carrier Free,His Tag,≥90%(SDS-PAGE) | Suitable for caspase-8-related enzymology studies | |
Caspase-8 inhibitor | Caspase-8 inhibitor II | ≥98% | Suitable for TWEAK-related apoptosis blockade experiments | |
Caspase-8 inhibitor | Q-IETD-OPh |
| Suitable for caspase-8 inhibition validation | |
Caspase-8 inhibitor | Z-IETD-FMK | ≥99% | Suitable for intracellular caspase-8 inhibition experiments | |
Caspase-3 antibody | Caspase 3 Mouse mAb | Carrier Free, Validated, ExactAb™, Azide Free, High Performance, PBS Only, ≥95%(SDS-PAGE), 1.0 mg/mL | Suitable for detection of caspase-3, a core downstream execution-layer readout of TWEAK-induced apoptosis | |
Caspase-3 antibody | Caspase 3 Mouse mAb | Carrier Free,ExactAb™,Azide Free,Validated,High Performance,PBS Only,≥95%(SDS-PAGE),1.0 mg/mL | Suitable for caspase-3 detection | |
Recombinant Caspase-3 antibody | Recombinant Caspase3 Antibody | ExactAb™, Validated, Recombinant, 0.9mg/mL | Suitable for caspase-3 protein detection | |
Pro Caspase-3 antibody | Pro caspase 3 Antibody | KD Validation | Suitable for detecting pro-caspase-3 status | |
Caspase-3 inhibitor | Z-DEVD-FMK | ≥98% | Suitable for blockade experiments targeting TWEAK downstream execution-phase apoptosis | |
Caspase-3/7 inhibitor | Caspase-3/7 Inhibitor | ≥97% | Suitable for validation of executioner caspase dependence | |
Caspase-3 activator | PAC-1 | Moligand™, ≥98% | Suitable for construction of a caspase-3 activation control system | |
Recombinant Caspase-3 protein | Recombinant Human Caspase-3 Protein | ≥90%(SDS-PAGE) | Suitable for caspase-3-related enzymology studies | |
Recombinant Caspase-3 protein | Recombinant Human Caspase-3 Protein | Carrier Free,His Tag,≥90%(SDS-PAGE) | Suitable for caspase-3-related enzymology studies | |
Caspase-9 chromogenic substrate | Caspase-9 substrate (chromogenic) | ≥98% | Suitable for detecting caspase-9 activation in the mitochondrial amplification branch | |
Caspase-9 chromogenic substrate | Caspase-9 substrate (chromogenic) | ≥95%(HPLC), 20mM | Suitable for detecting caspase-9 activation | |
Caspase-9 antibody | Caspase-9 Mouse mAb | ExactAb™, Validated, 2.05 mg/mL | Suitable for caspase-9 protein detection | |
Caspase-9 antibody | Caspase-9 Mouse mAb | Carrier Free,ExactAb™,Azide Free,Validated,High Performance,PBS Only,≥95%(SDS-PAGE),1.0 mg/mL | Suitable for caspase-9 protein detection | |
Caspase-9 activity assay kit | Caspase 9 Activity Assay Kit | BioReagent,Suitable for Analysis, Colorimetry | Suitable for colorimetric detection of caspase-9 activity | |
Caspase-9 inhibitor | Caspase-9 Inhibitor III | ≥95% | Suitable for blockade experiments targeting the mitochondrial amplification branch | |
Caspase-9 inhibitor | Z-LEHD-FMK | ≥98% | Suitable for caspase-9 inhibition validation | |
Recombinant Caspase-9 antibody | Recombinant Caspase-9 Antibody | Recombinant, ExactAb™, Validated, See COA | Suitable for caspase-9 protein detection | |
Cleaved Caspase-9 antibody | Recombinant cleaved Caspase-9 Antibody | KD Validation | Suitable for detecting cleaved caspase-9 | |
Recombinant Caspase-9 protein | Recombinant Human Caspase-9 Protein | Carrier Free,His Tag,≥90%(SDS-PAGE) | Suitable for caspase-9-related enzymology studies | |
Recombinant Caspase-9 protein | Recombinant Human Caspase-9 Protein | ≥90%(SDS-PAGE) | Suitable for caspase-9-related enzymology studies | |
Pan-caspase inhibitor | Boc-D-FMK | ≥90% | Suitable for broad-spectrum validation of caspase dependence in TWEAK-induced or TWEAK-sensitized cell death |
The core feature of the TWEAK-Fn14 pathway is that it is not a unidirectional pro-apoptotic pathway, but rather a tissue response pathway built upon inducible Fn14 expression, centered on TRAF-cIAP rearrangement, and capable of coupling both canonical and non-canonical NF-κB signaling with cell death sensitization modules.
For more related articles, please see below:
[2] Wnt/β-Catenin Signaling Pathway
[4] Metabolic signaling pathway
[5] Wnt Signaling
[7] JAK-STAT Cell Signaling Pathway
[8] PD-1/PD-L1 Signaling Pathway
References
[1] Kumar M, Makonchuk DY, Li H, Mittal A, Kumar A. TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1. J Immunol. 2009;182(4):2439-2448.
[2] Yepes M. TWEAK and the central nervous system. Mol Neurobiol. 2007;35(3):255-265. Review.
[3] Perper SJ, Browning B, Burkly LC, et al. TWEAK is a novel arthritogenic mediator. J Immunol. 2006;177(4):2610-2620.